Tumor suppressor miR‐193a‐3p enhances efficacy of BRAF/MEK inhibitors in BRAF‐mutated colorectal cancer

Patients with BRAF‐mutated colorectal cancer (CRC) have a poor prognosis despite recent therapeutic advances such as combination therapy with BRAF, MEK, and epidermal growth factor receptor (EGFR) inhibitors. To identify microRNAs (miRNAs) that can improve the efficacy of BRAF inhibitor dabrafenib (...

Descripción completa

Detalles Bibliográficos
Autores principales: Hiraide, Sakura, Takahashi, Masanobu, Yoshida, Yuya, Yamada, Hideharu, Komine, Keigo, Ishioka, Chikashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409311/
https://www.ncbi.nlm.nih.gov/pubmed/34288281
http://dx.doi.org/10.1111/cas.15075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409311/
https://www.ncbi.nlm.nih.gov/pubmed/34288281
http://dx.doi.org/10.1111/cas.15075

Ejemplares similares